NCT03012594View on ClinicalTrials.gov

Lanreotide in the Treatment of Small Bowel Motility Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

October 21, 2018

Study Completion Date

March 11, 2019

Conditions
Gastrointestinal Motility DisorderIntestinal Disease
Interventions
DRUG

Lanreotide

Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart

Trial Locations (2)

10075

Lenox Hill Hospital, New York

11040

Long Island Jewish Medical Center, New Hyde Park

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Northwell Health

OTHER

NCT03012594 - Lanreotide in the Treatment of Small Bowel Motility Disorders | Biotech Hunter | Biotech Hunter